ClinicalTrials.Veeva

Menu

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

AstraZeneca logo

AstraZeneca

Status and phase

Enrolling
Phase 2

Conditions

Gastric Cancer

Treatments

Drug: AZD0901
Drug: Capecitabine
Drug: 5-Fluorouracil
Drug: FOLFOX
Drug: AZD7789
Drug: XELOX
Drug: Rilvegostomig
Drug: Volrustomig

Study type

Interventional

Funder types

Industry

Identifiers

NCT05702229
2022-002840-29 (EudraCT Number)
D7986C00001

Details and patient eligibility

About

This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.

Full description

Approximately 240 participants will be assigned across 6 substudies, with approximately 40 evaluable participants of the confirmed recommend dose by SRC for study intervention in each corresponding substudy.

Enrollment

240 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • 18 years or older at the time of signing the ICF.
  • Body weight > 35 kg.
  • Previously untreated for unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
  • Has measurable target disease assessed by the Investigator based on RECIST 1.1.
  • ECOG PS zero or one.
  • Life expectancy of at least 12 weeks.
  • Adequate organ and bone marrow function.
  • Has central lab confirmed Claudin18.2 status at screening from archival tumour collected within past 24 months or from a fresh biopsy when Substudy 3, Substudy 4 or Substudy 6 is open for recruitment.

Exclusion criteria

  • Participants with HER2-positive (3+ by IHC, or 2+ by IHC and positive by in situhybridisation) or indeterminate gastric or GEJ carcinoma.
  • Untreated or progressive CNS metastatic disease, any leptomeningeal disease, or cord compression.
  • Participants with ascites which cannot be controlled with appropriate interventions.
  • Active infectious diseases, including tuberculosis, HIV infection, or hepatitis B/C.
  • Uncontrolled intercurrent illness.
  • Active or prior documented autoimmune or inflammatory disorders requiring systemic treatment with steroids or other immunosuppressive treatment.
  • History of another primary malignancy.
  • Previous treatment with an immune-oncology agent.
  • Previous treatment with any modalities of Claudin18.2 target therapy or MMAE exposure (when Substudy 3, Substudy 4, or Substudy 6 is open for recruitment).

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

240 participants in 6 patient groups

Substudy 1
Experimental group
Description:
Volrustomig plus XELOX (oxaliplatin and capecitabine) or FOLFOX (oxaliplatin and 5-FU/CF)
Treatment:
Drug: Volrustomig
Drug: XELOX
Drug: FOLFOX
Substudy 2
Experimental group
Description:
Rilvegostomig plus XELOX (oxaliplatin and capecitabine) or FOLFOX (oxaliplatin and 5-FU/CF)
Treatment:
Drug: Rilvegostomig
Drug: XELOX
Drug: FOLFOX
Substudy 3
Experimental group
Description:
AZD0901 plus volrustomig and 5-fluorouracil or capecitabine
Treatment:
Drug: Volrustomig
Drug: 5-Fluorouracil
Drug: Capecitabine
Drug: AZD0901
Substudy 4
Experimental group
Description:
AZD0901 plus rilvegostomig and 5-fluorouracil or capecitabine
Treatment:
Drug: Rilvegostomig
Drug: 5-Fluorouracil
Drug: Capecitabine
Drug: AZD0901
Substudy 5
Experimental group
Description:
AZD7789 plus XELOX (oxaliplatin and capecitabine) or FOLFOX (oxaliplatin and 5-FU/CF)
Treatment:
Drug: XELOX
Drug: AZD7789
Drug: FOLFOX
Substudy 6
Experimental group
Description:
AZD0901 plus AZD7789 and 5-fluorouracil or capecitabine
Treatment:
Drug: AZD7789
Drug: 5-Fluorouracil
Drug: Capecitabine
Drug: AZD0901

Trial contacts and locations

43

Loading...

Central trial contact

AstraZeneca Clinical Study Information Center

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems